Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative breast cancer (TNBC), but could be heading for use in previously untreated ...
Kroskey added that the folded radius forms as the metal is forced upward, in contact with the nose of the clamping tool, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results